• 1
    Chavassieux P, Pastoureau P, Boivin G, Delmas PD, Chapuy MC, Meunier PJ 1990 Effects on ewe bone remodeling of a low dose of disodium monofluorophosphate. Influence of a calcium supplement. In: ChristiansenC, OvergaardK (eds.) Osteoporosis 1990. Osteopress ApS, Copenhagen, Denmark, pp. 721723.
  • 2
    Chavassieux P, Pastoureau P, Boivin G, Chapuy MC, Delmas PD, Milhaud G, Meunier PJ 1991 Fluoride-induced bone changes in lambs during and after exposure to sodium fluoride. Osteoporos Int 2:2633.
  • 3
    Chavassieux P, Pastoureau P, Boivin G, Chapuy MC, Delmas PD, Meunier PJ 1991 Dose effects on ewe bone remodeling of short-term sodium fluoride administration—a histomorphometric and biochemical study. Bone 12:421427.
  • 4
    Chavassieux P, Pastoureau P, Chapuy MC, Delmas PD, Meunier PJ 1993 Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: A biochemical and histomorphometric study. Osteoporos Int 3:97102.
  • 5
    Chavassieux P, Buffet A, Vergnaud P, Garnero P, Meunier PJ 1997 Short-term effects of corticosteroids on trabecular bone remodeling in old ewes. Bone 20:451455.
  • 6
    Pastoureau P, Arlot ME, Caulin F, Barlet JP, Meunier PJ, Delmas PD 1989 Effects of oophorectomy on biochemical and histological indices of bone turnover in ewes. J Bone Miner Res 4;:S1:S237.
  • 7
    Hornby SB, Ford SL, Mase CA, Evans GP 1995 Skeletal changes in the ovariectomized ewe and subsequent response to treatment with 17β oestradiol. Bone 17:389S394S.
  • 8
    Turner AS, Mallinckrodt CH, Alvis MR, Bryant HU 1995 Dose-response effects of oestradiol implants on bone mineral density in ovariectomized ewes. Bone 17:421S427S.
  • 9
    Turner AS, Alvis MR, Mallinckrodt CH, Myers W, Stevens ML, Lundy MW 1995 Changes in bone mineral density and bone-specific alkaline phosphatase in ovariectomized ewes. Bone 17:395S402S.
  • 10
    Goldstein SR 1998 Selective estrogen receptor modulators: A new category of therapeutic agents for extending the health of postmenopausal women. Am J Obstetr Gynecol 179:14791484.
  • 11
    Gustafsson JA 1998 Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 2:508511.
  • 12
    Ammann P, Bourrin S, Bonjour JP, Brunner F, Meyer JM, Rizzoli R 1999 The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats. Osteoporos Int 10:369376.
  • 13
    Pastoureau P, Merle B, Delmas PD 1988 Specific radioimmunoassay for ovine bone-Gla protein. Acta Endocrinol (Copenh) 113:152160.
  • 14
    Garnero P, Delmas PD 1993 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:10461053.
  • 15
    Bonde M, Quist P, Fledelius C, Riis BJ, Christiansen C 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:20222025.
  • 16
    Chavassieux P, Arlot M, Meunier PJ 1996 Clinical use of bone biopsy. In: MarcusR, FeldmanD, KelseyJ (eds.) Osteoporosis. Academic Press, San Diego, CA, USA, pp. 11131121.
  • 17
    Roux JP, Arlot ME, Robert JP, Meunier PJ 1996 A new automatic method for the analysis of 2-D trabecular bone connectivity. Bone 19(Suppl):160S.
  • 18
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott S, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols and units. J Bone Miner Res 2:595610.
  • 19
    Kragstrup J, Gundersen HJG, Melsen F, Mosekilde L 1982 Estimation of the three-dimensional wall thickness of completed remodeling sites in iliac trabecular bone. Metab Bone Dis Rel Res 4:113119.
  • 20
    Compston JE, Mellish R, Groucher P, Newcombe R 1989 Structural mechanisms of trabecular bone loss in man. Bone Miner 6:339350.
  • 21
    Turner RT, Riggs BL, Spelberg TC 1994 Skeletal effects of estrogen. Endocr Rev 15:275300.
  • 22
    Black LJ, Masahiko S, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolick CA, Termine JD, Bryant HU 1994 Raloxifene (LY 139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:6369.
  • 23
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:16411647.
  • 24
    Chen HK, Ke HZ, Jee WSS, Ma YF, Pirie CM, Simmons HA, Thompson DD 1995 Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: A dual-energy X-ray absorptiometric and histomorphometric study. J Bone Miner Res 10:12561262.
  • 25
    Ke HZ, Chen HK, Qi H, Pirie CM, Simmons HA, Ma YF, Jee WSS, Thompson DD 1995 Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Bone 17:491496.
  • 26
    Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD 1995 Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136:24352441.
  • 27
    Nuttall ME, Bradbeer JN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H, Rehm S, Gowen M 1998 Idoxifene: A novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology 139:52245234.